Millipore Sigma Vibrant Logo
 

ecm550mm


32 Results Advanced Search  
Showing
Products (0)
Documents (32)
Site Content (0)

Narrow Your Results Use the filters below to refine your search

Document Type

  • (15)
  • (12)
  • (2)
  • (1)
  • (1)
  • Show More
Can't Find What You're Looking For?
Contact Customer Service

 

  • Cell Invasion Assay Kit

    Document Type:
    User Guide
    Product Catalog Number:
    ECM550
    Product Catalog Name:
    QCM ECMatrix Cell Invasion Assay, 24-well (8 µm), colorimetric

  • Combination of paclitaxel- and retinoic acid-incorporated nanoparticles for the treatment of cT-26 colon carcinoma. 21547672

    The aim of this study was to evaluate the antitumor effect of combinatorial targeted therapy with paclitaxel and all-trans retinoic acid (ATRA) nanoparticles in vitro. Paclitaxel-incorporated pullulan acetate (PA) nanoparticles were prepared by the nanoprecipitation-solvent evaporation method. ATRA-incorporated nanoparticles were prepared by dialysis using a methoxy poly(ethylene glycol)-grafted chitosan (ChitoPEG) copolymer. Particle sizes of paclitaxel-incorporated nanoparticles and ATRA-incorporated nanoparticles were about 160 nm and 60 nm, respectively. Nanoparticles were reconstituted in various aqueous media such as deionized water, phosphate-buffered saline, and fetal bovine serum-supplemented cell culture media. The combination of paclitaxel + ATRA (10 + 10 μg/mL) delivered by nanoparticles showed a synergistic antiproliferative effect against CT26 cells that was not observed with other combinations. Furthermore, the activity of MMP-2, a key enzyme in tumor cell invasion, was significantly decreased in cells treated with the combination of paclitaxel and ATRA while other combinations and single agents did not significantly affect its activity. A matrigel assay supported these results, indicating that paclitaxel/ATRA combination nanoparticles are effective for the inhibition of the invasion of tumor cells. The results of the present study suggest that combination treatment with paclitaxel and ATRA could be an effective treatment for the inhibition of tumor cell proliferation and invasion, and that nanoparticles are promising candidates for antitumor drug delivery.
    Document Type:
    Reference
    Product Catalog Number:
    ECM550
    Product Catalog Name:
    QCM ECMatrix Cell Invasion Assay, 24-well (8 µm), colorimetric

  • The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. 19375915

    A number of recent researches have demonstrated the therapeutic effects of glucosamine (Glc) in a range of human diseases including arthritis. For the first time, we identified that a novel Glc derivative having quaternized amino functionality (QAGlc) suppresses MMP-9 and MMP-2, gelatinases in HT1080, human fibrosarcoma cells at 40microg/ml, following stimulation with PMA. Reporter gene assay results revealed that, the mechanism of suppression involves decreased transcriptional activation of MMP-9 and MMP-2 via transcription factors NF-kappaB and AP-1. However based on western blot results, QAGlc did not attenuate the nuclear translocation of both NF-kappaB and AP-1. Apparently, phorbol myristate acetate (PMA) stimulated expressions of ERK, JNK and p38 were altered in the presence of potent tumour inducer, phorbol myristate acetate QAGlc, suggesting their suppression also contributes to QAGlc-mediated inhibition of MMP-9 and MMP-2. Moreover, the ability of QAGlc to inhibit gelatinases was confirmed by its ability to act against invasiveness of HT1080 cells through extracellular matrix components.
    Document Type:
    Reference
    Product Catalog Number:
    ECM550
    Product Catalog Name:
    QCM ECMatrix Cell Invasion Assay, 24-well (8 µm), colorimetric